Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03005054 · ClinicalTrials.gov registry record · Phase 2
StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects
A Phase 2 study, sponsored by Stratatech, a Mallinckrodt Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03005054 is a Phase 2 study that was terminated before completion, run by Stratatech, a Mallinckrodt Company. The registered enrollment target is 3 participants.
The verdict
NCT03005054, a Phase 2 study, was terminated before completion, sponsored by Stratatech, a Mallinckrodt Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
About 20 participants will be enrolled in this trial if they have had an accident that damages both the dermal (outside) and epidermal (inside) layers of skin on up to 49% of their body. This condition is called full-thickness complex skin defects resulting from acute traumatic skin loss. Participants will be treated with StrataGraft skin tissue to evaluate it's safety and effectiveness for use in treating full-thickness complex skin defects.
Interventions
- BIOLOGICAL StrataGraft Skin Tissue
- PROCEDURE Autograft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2019-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03005054
The ClinicalTrials.gov registry entry for NCT03005054 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stratatech, a Mallinckrodt Company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which StrataGraft Skin Tissue is the first listed.
NCT03005054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03005054 about?
NCT03005054 is a clinical study titled "StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects". About 20 participants will be enrolled in this trial if they have had an accident that damages both the dermal (outside) and epidermal (inside) layers of skin on up to 49% of their body. This condition is called full-thickness complex skin defects resulting from acute traumatic skin loss. Particip...
What is the current status of trial NCT03005054?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-04-24. Estimated completion is 2019-03-26.
What interventions are being tested in trial NCT03005054?
The interventions under investigation include: StrataGraft Skin Tissue (BIOLOGICAL), Autograft (PROCEDURE).
Who is sponsoring clinical trial NCT03005054?
This trial is sponsored by Stratatech, a Mallinckrodt Company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.